Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07343024 · ClinicalTrials.gov registry record
Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
A clinical trial of Advanced Cancer, sponsored by Cancer Commons.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07343024 is a study of Advanced Cancer that is actively recruiting participants, run by Cancer Commons. The registered enrollment target is 300 participants, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (23% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07343024, a study of Advanced Cancer, is actively recruiting participants, sponsored by Cancer Commons.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a successful clinical trial, the drug is not included in the National Comprehensive Cancer Network (NCCN) guidelines list of approved drugs for that cancer. The absence of a drug in the NCCN Guidelines for a particular cancer is usually not an indication that the drug has been shown to be ineffective for patients with that cancer. Rather, it is an indication that there is insufficient clinical trial evidence to include it. A drug that is FDA-approved for one or more cancers but is not in the NCCN Guidelines for a particular cancer is called an "off-guideline" drug for that cancer. This study is being done to measure and compare the reliability of multiple different treatment selection tests to predict a participant's response to an off- guideline cancer therapy. The results can guide oncologists to effective off-guideline drugs that would otherwise not be available to their advanced cancer patients. As this is an observational study, all the data gathered and analyzed will be generated in the normal practice of medicine, not by the study.
Conditions Studied
Study Locations (1)
California
- Cancer Commons - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07343024
The ClinicalTrials.gov registry entry for NCT07343024 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (23% higher). The listed sponsor is Cancer Commons, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07343024 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07343024 about?
NCT07343024 is a clinical study titled "Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)". Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a successful clinical trial, the drug is not included in the National Comprehensive Cancer Network (N...
What is the current status of trial NCT07343024?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-03. Estimated completion is 2028-12.
What conditions does trial NCT07343024 study?
This clinical trial studies the following conditions: Advanced Cancer.
Who is sponsoring clinical trial NCT07343024?
This trial is sponsored by Cancer Commons, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07343024 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.